Your browser is no longer supported. Please, upgrade your browser.
BNTX [NASD]
BioNTech SE
Index- P/E17.63 EPS (ttm)19.23 Insider Own1.18% Shs Outstand244.06M Perf Week3.63%
Market Cap85.30B Forward P/E7.69 EPS next Y44.09 Insider Trans0.00% Shs Float215.94M Perf Month2.17%
Income4.79B PEG- EPS next Q11.58 Inst Own16.50% Short Float0.98% Perf Quarter49.94%
Sales9.14B P/S9.33 EPS this Y107.10% Inst Trans20.67% Short Ratio0.51 Perf Half Y216.83%
Book/sh26.43 P/B12.83 EPS next Y7.78% ROA95.10% Target Price332.87 Perf Year405.99%
Cash/sh4.28 P/C79.26 EPS next 5Y- ROE158.10% 52W Range58.81 - 464.00 Perf YTD315.86%
Dividend- P/FCF- EPS past 5Y- ROI4.90% 52W High-26.94% Beta-
Dividend %- Quick Ratio2.60 Sales past 5Y- Gross Margin85.00% 52W Low476.45% ATR25.73
Employees2500 Current Ratio2.70 Sales Q/Q12630.20% Oper. Margin76.20% RSI (14)48.53 Volatility6.88% 5.75%
OptionableYes Debt/Eq0.22 EPS Q/Q- Profit Margin52.40% Rel Volume0.80 Prev Close359.18
ShortableYes LT Debt/Eq0.09 EarningsAug 09 BMO Payout0.00% Avg Volume4.13M Price339.01
Recom2.50 SMA20-3.22% SMA503.19% SMA20077.79% Volume3,322,067 Change-5.62%
Aug-11-21Upgrade Bryan Garnier Neutral → Buy $451
Jul-19-21Resumed Wolfe Research Outperform $248
Jun-16-21Downgrade Redburn Neutral → Sell $146
May-18-21Initiated Goldman Neutral $173
May-11-21Downgrade Bryan Garnier Buy → Neutral $135 → $206
Dec-01-20Downgrade BofA Securities Buy → Neutral $123 → $126
Aug-03-20Resumed Berenberg Buy $98
Jul-21-20Upgrade BofA Securities Neutral → Buy $71 → $105
Jun-30-20Downgrade H.C. Wainwright Buy → Neutral
May-19-20Upgrade H.C. Wainwright Neutral → Buy $48 → $69
Apr-28-20Downgrade BofA/Merrill Buy → Neutral $46 → $51
Mar-18-20Downgrade JP Morgan Overweight → Neutral $23 → $33
Mar-09-20Initiated H.C. Wainwright Neutral $30
Jan-24-20Downgrade SVB Leerink Outperform → Mkt Perform
Jan-22-20Downgrade UBS Buy → Neutral $35
Nov-05-19Initiated Wolfe Research Outperform
Nov-04-19Initiated UBS Buy $21
Nov-04-19Initiated SVB Leerink Outperform
Nov-04-19Initiated JP Morgan Overweight $23
Nov-04-19Initiated Canaccord Genuity Buy $22
Sep-20-21 05:46PM  
04:50PM  
04:09PM  
03:54PM  
03:52PM  
03:47PM  
01:42PM  
12:44PM  
11:16AM  
10:38AM  
09:56AM  
09:48AM  
09:04AM  
08:48AM  
08:16AM  
06:57AM  
06:45AM  
06:45AM  
06:45AM  
Sep-18-21 03:40AM  
Sep-17-21 07:21PM  
04:58PM  
04:26PM  
03:59PM  
03:56PM  
03:34PM  
02:09PM  
01:42PM  
11:17AM  
Sep-16-21 05:29PM  
04:15PM  
03:08PM  
10:54AM  
09:51AM  
05:55AM  
04:39AM  
Sep-15-21 11:15PM  
05:00PM  
04:25PM  
04:07PM  
04:00PM  
01:51PM  
01:20PM  
11:56AM  
09:29AM  
08:43AM  
08:15AM  
07:47AM  
06:10AM  
Sep-14-21 05:53PM  
04:07PM  
10:00AM  
08:25AM  
07:55AM  
Sep-13-21 04:04PM  
03:33PM  
01:40PM  
10:40AM  
03:52AM  
Sep-10-21 04:12PM  
01:58PM  
10:49AM  
08:14AM  
06:35AM  
06:08AM  
02:42AM  
Sep-09-21 02:24PM  
02:21PM  
11:51AM  
09:34AM  
06:52AM  
05:52AM  
Sep-08-21 01:37PM  
Sep-07-21 04:05PM  
02:12PM  
11:11AM  
Sep-06-21 08:25PM  
06:29PM  
08:26AM  
Sep-05-21 11:51PM  
08:55AM  
07:55AM  
Sep-03-21 04:05PM  
01:58PM  
01:08PM  
01:06PM  
12:47PM  
09:26AM  
06:50AM  
06:00AM  
Sep-02-21 04:48PM  
03:46PM  
02:18PM  
11:03AM  
10:26AM  
07:42AM  
06:18AM  
Sep-01-21 11:44PM  
09:20PM  
07:44PM  
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.